Shanghai Bio-heart Biological Technology Valuation
Is 2185 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2185 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2185's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2185's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2185?
Key metric: As 2185 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 2185's PB Ratio? | |
|---|---|
| PB Ratio | 0.5x |
| Book | CN¥722.58m |
| Market Cap | CN¥402.34m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2185's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
1612 Vincent Medical Holdings | 0.5x | 9.0% | HK$264.6m |
6609 Shanghai HeartCare Medical Technology | 0.7x | 111.8% | HK$762.1m |
2216 Broncus Holding | 0.2x | n/a | HK$242.5m |
2297 Rainmed Medical | 0.3x | n/a | HK$175.2m |
2185 Shanghai Bio-heart Biological Technology | 0.5x | n/a | HK$433.3m |
Price-To-Book vs Peers: 2185 is expensive based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.4x).
Price to Book Ratio vs Industry
How does 2185's PB Ratio compare vs other companies in the HK Medical Equipment Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
2216 Broncus Holding | 0.2x | n/a | US$31.14m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: 2185 is good value based on its Price-To-Book Ratio (0.5x) compared to the Hong Kong Medical Equipment industry average (1x).
Price to Book Ratio vs Fair Ratio
What is 2185's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2185's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sinopharm Group
HK$63.0b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.20
7D
-0.2%
1Y
8.0%
OrbusNeich Medical Group Holdings
HK$3.6b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.35
7D
5.6%
1Y
-45.6%
Sisram Medical
HK$1.6b
Engages in the research, design, development, manufacture, and sales of medical aesthetics and dental equipment, home use devices, injectables, and cosmeceuticals products in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.
1696
HK$3.34
7D
-6.7%
1Y
-41.1%